Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29861959 | 0.81 | ADORA2A (0.42) | ADORA2AADORA1 | |
| SCHEMBL358864 | 0.81 | ADORA2A (0.42) | ADORA2AADORA1 | |
| SCHEMBL19117793 | 0.65 | ADORA3 (0.48) | ADORA2AADORA1 | |
| SCHEMBL22241885 | 0.64 | MAPK6 (0.47) | — | |
| SCHEMBL996451 | 0.64 | ADORA2A (0.42) | ADORA2AADORA1 | |
| SCHEMBL27924344 | 0.63 | CXCR4 (0.40) | MEN1KMT2AHTR2C | |
| SCHEMBL28253318 | 0.62 | ADORA2A (0.40) | PRKCIADORA2AADORA1 | |
| Piperazine SCHEMBL21803298 | 0.62 | HTR2C (0.43) | MEN1KMT2AHTR2C | |
| SCHEMBL6105107 | 0.60 | KDM4E (0.39) | RAB9A | |
| SCHEMBL30960690 | 0.60 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271979-B2 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271980-B2 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2016-03-01 | — | — | US | disclosed |
| US-8618116-B2 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130040957-A1 | Deuterium-Enriched Pyrimidine Compounds and Derivatives | Dhanoa, Daljit Singh (US) | 2013-02-14 | — | — | US | disclosed |
| US-20120035191-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110028496-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028496-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DPYD, DHPS, DHODH | MEN1 4284/4885KMT2A 3655/4885NPC1 530/4885 |
| US-20120035191-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DBH, OPRK1, PYGB | MEN1 2678/4885KMT2A 4095/4885NPC1 652/4885 |
| US-20130040957-A1 | Deuterium-Enriched Pyrimidine Compounds and Derivatives | HTR2C, HTR2A, HTR5A | MEN1 1902/4885KMT2A 1990/4885NPC1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.